The lead program at Tonix Pharmaceuticals Holding Corp., a medicine aimed at delivering bedtime relief from symptoms of military-related post-traumatic stress disorder (PTSD), failed to adequately separate from placebo in an interim analysis of 12-week phase III data. News of the setback, the second pivotal miss for the drug, sent company shares (NASDAQ:TNXP) down 65.8 percent to $1.35 on Friday, as Tonix pursued hopes that the FDA might judge a future study by a data cut more favorable to the drug.